An amino acid transporter named xCT may affect the growth and progression of non-small cell lung cancer, a discovery that may predict the five-year survival rate of patients suffering from this cancer, now at 16 percent, researchers have concluded.
An amino acid transporter named xCT may affect the growth and progression of non-small cell lung cancer, a discovery that may predict the five-year survival rate of patients suffering from this cancer, now at 16 percent, researchers have concluded.